Hepatitis B immune globulin - Kamada
Alternative Names: HepaGam B; ImmunoGamLatest Information Update: 19 May 2023
Price :
$50 *
At a glance
- Originator Cangene Corporation
- Developer Aptevo Therapeutics; Emergent BioSolutions; Kamada; Saol Therapeutics
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 31 Dec 2022 Launched for Hepatitis B (Prevention of relapse) in United Arab Emirates (IV) as of December 2022
- 31 Dec 2022 Launched for Hepatitis B (Prevention) in United Arab Emirates (IM) as of December 2022
- 31 Dec 2022 Preregistration for Hepatitis B (Prevention of relapse) in Saudi Arabia (IV) as of December 2022